Company Thesis
Antares Pharma's (ATRS) flagship product XYOSTED administered as an injection for testosterone replacement therapy has seen monstrous growth with prescription volume breaking through the 10,000 units/mo. mark in December 2019. While the company is not profitable, its net loss is not increasing as revenue compounds. Without further ado, let's take a look as to why the company's buy rating will be reiterated today.
XYOSTED Growth
Source: Bloomberg Terminal
Source: Bloomberg Terminal
Since its launch in late 2018, XYOSTED has witnessed a momentous growth in terms of prescription volume. As of Dec